Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 2

2(50.0%)

4Total

Phase 1(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07430592Phase 2Not Yet Recruiting

This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria

Role: collaborator

NCT05905432Phase 1Completed

Pan-Malaria Transmission-Blocking Vaccine AnAPN1

Role: collaborator

NCT04709692Phase 2Completed

Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria

Role: collaborator

NCT05350462Unknown

Adoption of L-PZQ for Schistosomiasis by Endemic Counties - Social Science Research Study

Role: collaborator

NCT02661373Phase 1Completed

First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor

Role: collaborator

All 5 trials loaded